Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Kyverna Therapeutics, Inc. ( (KYTX) ) is now available.
On April 20, 2026, Kyverna Therapeutics reported positive longer-term Phase 2 follow-up data from the KYSA-6 Phase 2/3 trial of its CAR T candidate miv-cel in generalized myasthenia gravis, showing deepening responses, durable benefit out to 52 weeks, and 100% of patients remaining free of immunotherapies through at least 24 weeks. On April 21, 2026, the company announced positive primary analysis results from its registrational KYSA-8 trial in stiff person syndrome, where miv-cel delivered statistically significant and durable clinical benefit across endpoints, with all patients free of immunotherapies from week 16 through last follow-up, reinforcing Kyverna’s bid to secure the first approved autoimmune CAR T therapy and strengthening its commercial and regulatory position in high-unmet-need neuroimmunology indications.
The most recent analyst rating on (KYTX) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.
Spark’s Take on KYTX Stock
According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.
The score is held back primarily by weak financial performance—zero recent revenue alongside widening losses and accelerating cash burn—despite a low-debt balance sheet. Offsetting this, the stock shows strong bullish technicals (though overbought) and recent corporate events are positive, highlighted by encouraging Phase 2 durability/safety data and leadership additions.
To see Spark’s full report on KYTX stock, click here.
More about Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. is a biotechnology company focused on developing autoimmune-targeted chimeric antigen receptor T-cell (CAR T) therapies. Its lead candidate, miv-cel (mivocabtagene autoleucel, KYV-101), is a fully human, autologous CD19 CAR T-cell product designed for potency and tolerability, targeting B-cell–driven autoimmune diseases such as stiff person syndrome and generalized myasthenia gravis.
Average Trading Volume: 728,808
Technical Sentiment Signal: Strong Buy
Current Market Cap: $679.9M
See more insights into KYTX stock on TipRanks’ Stock Analysis page.